The former worker, Amit Dagar, and his friend and business partner, Atul Bhiwapurkar, are charged with violating antifraud laws. According to a lawsuit brought by the U.S. Securities and Exchange Commission, Mr. Dagar was a senior statistical program lead for the Paxlovid drug trial and, after finding out the trial met its endpoints, he and Mr. Bhiwapurkar purchased “short term, out-of-the-money Pfizer call options, including options that expired the very next day.”
With the investments, Mr. Dagar earned $214,395 and Mr. Bhiwapurkar made $60,300, the lawsuit alleges.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.